Boston Scientific Announces Canadian Approval For Its LATITUDE® Patient
Management System

    




    
</pre>
<p>NATICK, Mass., <span class="xn-chron">Oct. 25</span> /CNW/ -- <span class="xn-location">Boston</span> Scientific Corporation (NYSE: BSX) today announced Canadian regulatory approval and launch of its LATITUDE® Patient Management system.  The LATITUDE system enables physicians to remotely monitor patients with implantable cardiac devices, gathering information on both the device and a patient's heart health status.  The system can also detect clinical events between scheduled physician visits and send relevant data directly to a patient's physician.</p>
<p/>
<p>"<span class="xn-location">Boston</span> Scientific has enrolled more than 170,000 patients on the LATITUDE system since its introduction in the U.S. in 2006, making it the most rapidly adopted remote cardiac device monitoring system in the industry," said Hank Kucheman, Executive Vice President and President of <span class="xn-location">Boston</span> Scientific Cardiology, Rhythm and Vascular Group.  "We expect continued success as we introduce the demonstrated benefits of our LATITUDE system to patients and physicians in <span class="xn-location">Canada</span>.  Remote monitoring technology provides a significant opportunity to further impact patient care."</p>
<p/>
<p>LATITUDE is the only remote cardiac device monitoring system to offer a wireless weight scale and blood pressure monitor, both of which are recommended by the <span class="xn-org">American College</span> of Cardiology and American Heart Association physician societies for the management of heart failure patients.</p>
<p/>
<p>The Canadian version of the LATITUDE system is compatible with the Company's wireless COGNIS® cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN® implantable cardioverter defibrillator (ICD), the world's smallest and thinnest high-energy devices.</p>
<p/>
<p><span class="xn-location">Boston</span> Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: <a href="http://www.bostonscientific.com">www.bostonscientific.com</a>.</p>
<pre>
    

    Cautionary Statement Regarding Forward-Looking Statements

    
</pre>
<p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, product performance and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.</p>
<p/>
<p>Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.</p>
<pre>
    


    
</pre>
<p> </p>
<p> </p>
<pre>
    
    CONTACT:    Paul Donovan
                508-650-8541 (office)
                508-667-5165 (mobile)
                Media Relations
                Boston Scientific Corporation
    
</pre>
<p> </p>
<pre>
    
                David Knutson
                651-260-8288 (mobile)
                Media Relations
                Boston Scientific Corporation
    
</pre>
<p> </p>
<pre>
    
                Larry Neumann
                508-650-8696 (office)
                Investor Relations
                Boston Scientific Corporation










    

For further information: Media Relations: Paul Donovan, [phone] (office), or [phone] (mobile) or David Knutson, [phone] (mobile) or Investor Relations: Larry Neumann, [phone] (office), all of Boston Scientific Corporation Web Site: http://www.bostonscientific.com